Creative Medical Technology Holdings (CELZ) Gross Margin (2017 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly Gross Margin of 66.87% for Q4 2025, up 687.0% year-over-year from 8.5% in Q4 2024, and up 11.44% quarter-over-quarter from 60.0% in Q1 2025.
Creative Medical Technology Holdings (CELZ) Gross Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Gross Margin for 9 consecutive years, with 66.87% the latest figure, recorded in Q4 2025.
- In Q4 2025, Gross Margin rose 687.0% year-over-year to 66.87%; the TTM figure through Mar 2026 stood at 66.87% (up 687.0% YoY), while the FY2025 annual figure was 63.43%, up 343.0% from the prior year.
- Gross Margin rose to 66.87% in Q4 2025 per CELZ's latest filing, from 60.0% in the prior quarter.
- Across five years, Gross Margin topped out at 70.91% in Q3 2022 and bottomed at 41.78% in Q4 2021.
- Historically, Gross Margin has averaged 59.89% across 5 years, with a median of 60.0% in 2021.
- Annual changes were most pronounced in 2021 — Gross Margin sank 1714 bps — and 2022, when it surged 2758 bps.
- Creative Medical Technology Holdings' Gross Margin stood at 41.78% in 2021, then surged by 66 bps to 69.35% in 2022, then decreased by 13 bps to 60.0% in 2023, then changed by 0 bps to 60.0% in 2024, then rose by 11 bps to 66.87% in 2025.
- Business Quant data shows CELZ's Gross Margin at 66.87% in Q4 2025, 60.0% in Q1 2025, and 60.0% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 66.87% |
| Mar 31, 2025 | 60.00% |
| Dec 31, 2024 | 60.00% |
| Jun 30, 2024 | 60.00% |
| Dec 31, 2023 | 60.00% |
| Sep 30, 2023 | 60.00% |
| Dec 31, 2022 | 69.35% |
| Sep 30, 2022 | 70.91% |
| Mar 31, 2022 | 54.73% |
| Dec 31, 2021 | 41.78% |
| Sep 30, 2021 | 60.00% |
| Jun 30, 2021 | 55.00% |
| Dec 31, 2020 | 54.29% |
| Sep 30, 2020 | 77.14% |
| Jun 30, 2020 | 61.29% |
| Mar 31, 2020 | 66.28% |
| Dec 31, 2019 | 192.27% |
| Sep 30, 2019 | 86.09% |
| Jun 30, 2019 | 68.83% |
| Mar 31, 2019 | 71.97% |